Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenues Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenues Outlook

Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

March 16, 2020 5:27 PM EDT

-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million

-GAAP Net Income of $32 Million for Fiscal Year 2019

-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020

-Firdapse Supply Chain in Solid Position-Significant Safety Stock

-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More

Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

March 16, 2020 5:26 PM EDT

-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million

-GAAP Net Income of $32 Million for Fiscal Year 2019

-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020

-Firdapse Supply Chain in Solid Position-Significant Safety Stock

-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More